Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ana Clara Torre is active.

Publication


Featured researches published by Ana Clara Torre.


Clinics in Dermatology | 2012

Emerging systemic fungal infections

Ricardo Galimberti; Ana Clara Torre; María Carolina Baztán; Florencia Rodriguez-Chiappetta

Systemic mycoses are a heterogeneous group of infections caused by different species of fungi that mainly affect individuals with primary or secondary alterations of immunity. In recent years, there has been an increase in the incidence of infections related to migration, AIDS, and other causes of immunosuppression, such as solid organ and bone marrow transplantation; oncological, hematological, and autoimmune diseases; and the use of new drugs. In this paper, we outline the microbiological and epidemiological characteristics of 3 fungi: Aspergillus spp, Fusarium spp, and Penicillium spp. We describe the clinical manifestations of disease with emphasis on those that should alert the dermatologist to make an early diagnosis. We detail the various tools for early diagnosis, prevention, and the epidemiology of different antifungals available for treatment and their mechanism of action and therapeutic efficacy.


International Journal of Dermatology | 2009

Disseminated strongyloidiasis in immunocompromised patients – report of three cases

Ricardo Galimberti; Anahí Pontón; Fatima Agüero Zaputovich; Lorna Velásquez; Gastón Galimberti; Ana Clara Torre; Alicia Kowalczuk

Background  Strongyloides stercoralis is an intestinal nematode of humans. The characteristic cutaneous manifestation of strongyloidiasis is larva currens. Patients with suppressed immunity can develop a severe disseminated strongyloidiasis involving wide spread of the larvae to extraintestinal organs, outside the usual migration pattern. Patients with cell‐mediated immunodeficiency and on corticosteroid therapy appear to be at highest risk for the development of this highly fatal entity.


International Journal of Dermatology | 2017

Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients

Aldana Soledad Vacas; Ana Clara Torre; M.L. Bollea-Garlatti; Fernando Warley; Ricardo Galimberti

The aim of this study was to describe the clinical characteristics of patients with pyoderma gangrenosum (PG) and to evaluate the association between these characteristics, the treatment followed, and the patient responses, relapses, and mortality rates.


Journal of The American Academy of Dermatology | 2015

Dermoscopy aids the diagnosis of crusted scabies in an erythrodermic patient

Luis Agustín Bollea Garlatti; Ana Clara Torre; María Luz Bollea Garlatti; Ricardo Galimberti; Giuseppe Argenziano

the Department of Dermatology, Hospital Italiano de Buenos ires, and Skin Cancer Unit, Arcispedale Santa Maria Nuova tituto di Ricovero e Cura a Carattere Scientifico (IRCCS), ggio Emilia. ing sources: None. licts of interest: None declared. int requests: Luis Agust in Bollea Garlatti, MD, Department of ermatology, Hospital Italiano de Buenos Aires, Tte. Gral. Juan Domingo Per on 4190, C1199ABD, Ciudad Aut onoma de Buenos Aires, Argentina. E-mail: [email protected]. J Am Acad Dermatol 2015;73:e93-5. 0190-9622/


Journal of The European Academy of Dermatology and Venereology | 2016

Secondary syphilis with pulmonary involvement.

J. Riganti; M. Martin; Ana Clara Torre; G. Scalia; L. Clara; M. Vallone; Ricardo Galimberti

36.00 a 2015 by the American Academy of Dermatology, Inc. http://dx.doi.org/10.1016/j.jaad.2015.04.061


International Journal of Dermatology | 2014

Lingual ulceration associated with retinoic acid syndrome during treatment of acute promyelocytic leukemia

Julia Riganti; Mariana Paula Caviedes; Ana Clara Torre; Mariana Guzzi Maqueda; María Carolina Baztán Piñero; Victoria Volonteri; Ricardo Galimberti

tension when compared to controls. Importantly, a recent Danish nationwide study showed that a diagnosis of skin cancer was associated with less myocardial infarction, hip fracture and allcause mortality. A lower blood pressure due to sunlight exposure as suggested by our results could contribute to reduced risk of myocardial infarction and improved life expectancy in patients with skin cancer. Our study had limitations, e.g. we used skin cancer as a surrogate for sunlight exposure. However, a recent study showed that a high baseline VD3 status was a significant predictor of skin cancer but not of other cancers, compatible with VD3 being a surrogate for sustained high UVr exposure. While we attempted to adjust for socio-economic factors and smoking, residual unmeasured confounding factors (e.g., obesity) cannot be ruled out. We submit that our results and other emerging evidence on potentially favourable cardiovascular effects of sunlight should be carefully considered in future health policies, balancing the risks and benefits of sunlight exposure.


Anais Brasileiros De Dermatologia | 2018

Bullous pyoderma gangrenosum as a predictor of hematological malignancies

Aldana Soledad Vacas; M.L. Bollea-Garlatti; Ana Clara Torre; Ricardo Galimberti

All‐trans retinoic acid (ATRA) is routinely associated with chemotherapy for the treatment of acute promyelocytic leukemia (APL). Several reports of scrotal ulceration induced by this agent have been made in the recent years.


Journal of The European Academy of Dermatology and Venereology | 2017

Invasive Trichosporosis due to primary cutaneous infection.

Ricardo Galimberti; B.A. Hernández; Ana Clara Torre; L.A.B. Garlatti; M.E. Gil; D.C.V. Montero; M.P. Caviedes

Pyoderma gangrenosum may precede, coexist or follow diverse systemic diseases. The bullous variety is usually associated with hematologic disorders. From 31 patients with pyoderma gangrenosum diagnosed in our hospital during 10 years, only 2 presented with the bullous type. One patient had previous diagnosis of chronic myeloid leukemia. Both had fast-progressive, painful lesions, and both showed an excellent response to systemic corticosteroids. In less than 3 months the lesions recurred simultaneously with the progression of chronic myeloid leukemia in one patient and with the initial diagnosis of acute myeloid leukemia in the other one. They died in less than four weeks. These findings emphasize the importance of its timely diagnosis. Cutaneous lesions could be the first predictor of an underlying disease.Pyoderma gangrenosum may precede, coexist or follow diverse systemic diseases. The bullous variety is usually associated with hematologic disorders. From 31 patients with pyoderma gangrenosum diagnosed in our hospital during 10 years, only 2 presented with the bullous type. One patient had previous diagnosis of chronic myeloid leukemia. Both had fast-progressive, painful lesions, and both showed an excellent response to systemic corticosteroids. In less than 3 months the lesions recurred simultaneously with the progression of chronic myeloid leukemia in one patient and with the initial diagnosis of acute myeloid leukemia in the other one. They died in less than four weeks. These findings emphasize the importance of its timely diagnosis. Cutaneous lesions could be the first predictor of an underlying disease.


Anais Brasileiros De Dermatologia | 2017

Reactivation of Chagas-Mazza disease during treatment with infliximab

Aldana Soledad Vacas; Leidy Viviana Gomez-Santana; Ana Clara Torre; Ricardo Galimberti

1 Kirtschig G, Becker K, G€ unthert A et al. Evidence-based(S3) Guideline on (anogenital) Lichen sclerosus. J Eur Acad Dermatol Venereol 2015; 29: e1–e43. 2 Bunker CB, Shim TN. Male genital lichen sclerosus. Indian J Dermatol 2015; 60: 111–117. 3 Meuli M, Briner J, Hanimann B, Sacher P. Lichen sclerosus et atrophicus causing phimosis in boys: a prospective study with 5-year follow-up after complete circumcision. J Urol 1994; 152: 987–989. 4 Bunker CBB. Letter to the Editor to “EDF Lichen Sclerosus Guideline”. J Eur Adac Dermatol. [Accepted article for publication].


Actas Dermo-Sifiliográficas | 2017

Características clínicas y evolutivas de una población con herpes zoster diseminado: un estudio de cohorte retrospectiva

M.L. Bollea-Garlatti; L.A. Bollea-Garlatti; Aldana Soledad Vacas; Ana Clara Torre; A.M. Kowalczuk; Ricardo Galimberti; B.L. Ferreyro

Dear Editor, Chagas-Mazza disease is a zoonosis caused by Trypanosoma cruzi, a species of parasitic euglenoid protozoan. It affects 21 countries in the Americas, where 7 to 10 million people are infected, 8 out of 100,000 individuals/year, and it has a mortality rate of 12,000 individuals/year. The main routes of transmission are exposure to vectors (Triatoma infestans), transfusion (second in frequency), placental and oral transmission. Given increasing migration and organ and blood product donations, this disease has become global, affecting Europe and North America. 1 Chagas disease presents three well -defined clinical phases. The acute phase develops after an incubation phase that lasts from 4 to 10 days. The acute stage can be asymptomatic or present with fever, macular or inflammatory lesions in the inoculation site (chagoma), edema, palpebral unilateral induration (Romaña’s sign) or myocarditis. Of all infected people, only 1 to 2 % is diagnosed during this phase. The indeterminate chronic phase is characterized by the absence of symptoms and by standard laboratory test findings. Thirty percent of patients can remain in this phase during their entire life, while the remaining 70% evolve into the chronic or symptomatic phase, with heart or esophagus involvement. Reactivation may occur in immunosuppressed patients, especially in those patients that present an alteration of cell mediated immunity. It can be asymptomatic or manifest with neurologic, cardiac or cutaneous changes.2 PCR technique amplifies in vivo fragments of the parasite’s DNA. In immunosuppressed patients, PCR test is useful for the diagnosis and control of the disease, given the fact that ELISA serology can be negative in some patients. It also allows to make early diag-

Collaboration


Dive into the Ana Clara Torre's collaboration.

Top Co-Authors

Avatar

Ricardo Galimberti

Hospital Italiano de Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Gisela Vaglio Giors

Hospital Italiano de Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Aldana Soledad Vacas

Hospital Italiano de Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Daniela Malieni

Hospital Italiano de Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Alicia Kowalczuk

Hospital Italiano de Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Carolina Anselmi

Hospital Italiano de Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Paula A Enz

Hospital Italiano de Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Victoria Volonteri

Hospital Italiano de Buenos Aires

View shared research outputs
Top Co-Authors

Avatar

Gastón Galimberti

Hospital Italiano de Buenos Aires

View shared research outputs
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge